5-aminolevulinic acid (5-ALA) mediated interstitial photodynamic therapy (iPDT) is undergoing clinical trials for the treatment of malignant gliomas. 5-ALA iPDT is based on the creation of reactive oxygen species (ROS) via excitation of 5-ALA mediated protoporphyrin IX (PpIX) in the tumor cells and causing a phototoxic reaction. After iPDT local chemo-radiation is performed as adjuvant therapy. 16 newly diagnosed glioblastomas and 44 malignant glioma recurrences treated with 5-ALA iPDT in Munich were retrospectively analyzed for treatment outcome, spectral online monitoring and changes in the MRI. iPDT for newly diagnosed glioblastomas showed a median overall survival (OS) of 28 months, 16.4 months progression free survival (PFS), respectively. 43.8% patients with newly diagnosed glioblastoma experienced a long term PFS > 24 months. In addition, the methylation of the MGMT promotor showed to be a prognostic factor for prolonged survival (p=0.04). In case of recurrent malignant gliomas PFS after iPDT was 7.1 months with 25% >24 months survival after iPDT (17.9% PFS > 24 months). Analysis of spectral online monitoring showed that a measured decrease of the laser light transmission between the cylindrical diffuser fibers, used for the irradiation, can be associated with silent hemorrhages visible in terms of T1-hyperintensity in the MRI after iPDT. Overall 5-ALA iPDT is a promising tool for the treatment of glioblastomas and other malignant gliomas with prolonged survival and minimally invasive surgery.
Access to the requested content is limited to institutions that have purchased or subscribe to SPIE eBooks.
You are receiving this notice because your organization may not have SPIE eBooks access.*
*Shibboleth/Open Athens users─please
sign in
to access your institution's subscriptions.
To obtain this item, you may purchase the complete book in print or electronic format on
SPIE.org.
INSTITUTIONAL Select your institution to access the SPIE Digital Library.
PERSONAL Sign in with your SPIE account to access your personal subscriptions or to use specific features such as save to my library, sign up for alerts, save searches, etc.